Category: Press Release - Psychedelic Alpha

MYND Life Sciences Announces $3.5 Million Share Offering

Post published:April 21, 2022
Post category:Press Release

Read more about the article Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Post published:April 21, 2022
Post category:Press Release

Read more about the article COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers

COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers

Post published:April 20, 2022
Post category:Press Release

Read more about the article Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds

Post published:April 19, 2022
Post category:Press Release

Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural Psilocybin Products

Post published:April 19, 2022
Post category:Press Release

Read more about the article MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

Post published:April 14, 2022
Post category:Press Release

Numinus Wellness Inc. Reports Q2 2022 Results

Post published:April 14, 2022
Post category:Press Release

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Post published:April 13, 2022
Post category:Press Release

Filament Health Is Issued Patent By United States Patent And Trademark Office

Post published:April 13, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway

Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway

Post published:April 13, 2022
Post category:Press Release

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

MYND Life Sciences Announces $3.5 Million Share Offering

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds

Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural Psilocybin Products

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

Numinus Wellness Inc. Reports Q2 2022 Results

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Filament Health Is Issued Patent By United States Patent And Trademark Office

Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.